ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

Imagining a Life Free from the Pain of Ankylosing Spondylitis

Lara C. Pullen, PhD  |  September 30, 2019

Dan Reynolds, the lead singer of the Grammy award-winning band Imagine Dragons, has partnered with Novartis to increase awareness of ankylosing spondylitis.

Filed under:Axial SpondyloarthritisConditionsPsoriatic Arthritis Tagged with:Ankylosing SpondylitisMonster Pain in the ASNovartisplaque psoriasispsoriatic arthritissecukinumab

RheumPAC Advocates for Dept. of Defense Arthritis Research Funding

From the College  |  September 17, 2019

RheumPAC is the ACR’s non-partisan political action committee, which promotes the needs of rheumatology providers and patients. Advocacy efforts often focus on legislation to improve the day-to-day clinical care of rheumatology patients, such as establishing clinical exceptions to step therapy requirements and reforming the prior authorization process. In addition, the ACR and RheumPAC recognize the…

Filed under:From the CollegeLegislation & AdvocacyOsteoarthritis and Bone Disorders Tagged with:DoD research fundingResearch FundingRheumPAC

To Understand Lupus, Study the Gut

Elizabeth Hofheinz, MPH, MEd  |  September 17, 2019

Researchers who devote their time to studying lupus are accustomed to considering environmental stimuli such as sunshine and cigarettes. But according to Gregg J. Silverman, MD, a professor in the Department of Medicine and in the Department of Pathology at the New York University (NYU) School of Medicine and co-director of the Musculoskeletal Center of…

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:environmental factorgut microbiomeRuminococcus gnavus (RG)

Case Report: Diagnosing, Treating Hepatitis B-Linked Polyarteritis Nodosa

Naveen Raj, DO, & Lisa Duncan, MD   |  September 17, 2019

Hepatitis B virus (HBV) associated polyarteritis nodosa (PAN) is an increasingly rare vasculitis in developed countries due to advances in HBV vaccination and antiviral therapy. However, the condition does persist, and rheumatologists should consider it when evaluating vasculitis cases. Below, we discuss a case that illustrates the varied clinical presentations PAN can encompass. A high…

Filed under:ConditionsVasculitis Tagged with:case reporthepatitis Bpolyarteritis nodosa

The Role of Autoreactive B Cells in Rheumatoid Arthritis

Catherine Kolonko  |  September 17, 2019

The body uses B cells to produce antibodies that can fight off infection by invading antigens and bacteria. But in rheumatoid arthritis (RA), the immune system produces autoantibodies that work against the body’s proteins to attack joint tissues. Researchers believe this process is helped along by autoreactive B cells that live in bone matter and…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:amphiregulinautoreactive B cells

Case Report: Does a Rapid-Onset Neck Mass Have Rheumatic Origins?

Tej Bhavsar, MD, & Nancy Joste, MD  |  September 17, 2019

A 54-year-old African American man arrived at the emergency department with the acute onset of a tender mass on the left side of his neck. It had been getting progressively larger for the preceding two days. History & Examination His history included chronic right hip osteoarthritis with two surgeries performed five years prior. At his…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:AmyloidosisCancercase report

Intensive, Personalized Learning

Susan Bernstein  |  August 28, 2019

During the 2019 ACR/ARP Annual Meeting, the new Meet the Professor Workshops and sessions will feature hands-on training on state-of-the-art topics…

Filed under:Education & TrainingProfessional Topics Tagged with:2019 ACR/ARP Annual MeetingEducationeducation and training

Osteoporosis Drugs Don’t Reduce Overall Mortality

Megan Brooks  |  August 21, 2019

NEW YORK (Reuters Health)—Anti-fracture medications do not reduce overall mortality in older patients with osteoporosis, according to an updated systematic review and meta-analysis. “This meta-analysis suggests drug treatments, including treatment with bisphosphonates, for osteoporosis should be recommended only for the prevention of fracture and not for any additional reduction in mortality,” researchers write in JAMA…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:FracturesmortalityOsteoporosisosteoporosis treatments

Study Probes New Gene Therapy for Severe, Localized Scleroderma (Morphea)

Ruth Jessen Hickman, MD  |  August 16, 2019

In September 2018, the U.S. Food & Drug Administration (FDA) granted fast-track status to FCX‑013, a gene therapy product developed to treat moderate to severe localized scleroderma (morphea). Previously, the treatment received an orphan drug designation for localized scleroderma, as well as a rare pediatric disease designation. Phase 1 and 2 studies will assess safety…

Filed under:ConditionsSystemic Sclerosis Tagged with:FCX‑013gene therapymorpheasystemic sclerosis (SSc)

S K Chavan / shutterstock.com

Case Report: A Patient Helps Diagnose Familial Mediterranean Fever

Taylor Faulk, MD, & Matthew B. Carroll, MD  |  August 16, 2019

Autoinflammatory diseases are genetically diverse, but clinically similar, conditions distinct from autoimmune illnesses, such as systemic lupus erythematosus or rheumatoid arthritis. Clinically, they are defined by recurrent episodes of inflammation that follow a characteristic pattern each time they occur. Some have a set length of time during which fever, peritonitis or arthritis manifest. Others are…

Filed under:Conditions Tagged with:Familial Mediterranean fever

  • « Previous Page
  • 1
  • …
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 86
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences